Market Place
Sourcing Support
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
12 Oct 2023 //
GLOBENEWSWIRE
VBL Therapeutics Reminds Shareholders to Vote in the Annual Meeting
04 Oct 2023 //
GLOBENEWSWIRE
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger
06 Sep 2023 //
GLOBENEWSWIRE
VBL Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
VBL Therapeutics Reports 1Q 2023 FYR Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
VBL Therapeutics Reports Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility
09 Mar 2023 //
GLOBENEWSWIRE
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
23 Feb 2023 //
GLOBENEWSWIRE
After a tough year, VBL merges with Notable Labs
23 Feb 2023 //
FIERCE BIOTECH
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility
16 Feb 2023 //
GLOBENEWSWIRE
Cash-strapped VBL sells manufacturing plant for $7.1M
16 Feb 2023 //
FIERCE PHARMA
VBL Therapeutics Reports 3Q 2022 Financial Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid
01 Sep 2022 //
GLOBENEWSWIRE
VBL Therapeutics Announces Second Quarter 2022 Financial Result
15 Aug 2022 //
GLOBENEWSWIRE
VBL lays off 35% of staff after failure-induced stock shock
03 Aug 2022 //
FIERCEBIOTECH
VBL Therapeutics Announces Top-Line Data from PIII OVAL Trial of Ofra-Vec
19 Jul 2022 //
GLOBENEWSWIRE
VBL Therapeutics Reports First Quarter 2022 Financial Results
17 May 2022 //
GLOBENEWSWIRE
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
10 May 2022 //
GLOBENEWSWIRE
VBL Tx to Participate in Upcoming Scientific and Industry Conferences in May
03 May 2022 //
GLOBENEWSWIRE
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28 Apr 2022 //
GLOBENEWSWIRE
VBL Receives FDA Fast Track Designation for Ofra-Vec for the Treatment
26 Apr 2022 //
GLOBENEWSWIRE
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
31 Mar 2022 //
GLOBENEWSWIRE
VBL Tx Reports Full Year 2021 Financial Results and Provides Corporate Update
23 Mar 2022 //
GLOBENEWSWIRE
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
14 Mar 2022 //
GLOBENEWSWIRE
VBL Tx says Completion of Enrollment in OVAL P 3 Registration-Enabling Trial
08 Mar 2022 //
GLOBENEWSWIRE
VBL Therapeutics to Participate at March Investor Conferences
03 Mar 2022 //
GLOBENEWSWIRE
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15 Feb 2022 //
GLOBENEWSWIRE
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
06 Jan 2022 //
GLOBENEWSWIRE
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe
20 Dec 2021 //
GLOBENEWSWIRE
VBL Therapeutics Announces Appointment of Sam Backenroth as CFO
05 Oct 2021 //
GLOBENEWSWIRE
VBL Therapeutics gets clearance for OVAL Ph 3 Study of VB-111 in Ovarian Cancer
17 Sep 2021 //
GLOBENEWSWIRE
VBL Therapeutics Resumes U.S. Enrollment in OVAL PIII Trial
30 Aug 2021 //
GLOBENEWSWIRE
VBL Therapeutics Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors
22 Jul 2021 //
GLOBENEWSWIRE
VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors
22 Jul 2021 //
GLOBENEWSWIRE
VBL Therapeutics Appoints Alison Finger & Michael Rice to its Board of Directors
08 Jul 2021 //
GLOBENEWSWIRE
VBL Therapeutics Provides Update of VB-111 Study in Ovarian Cancer
15 Jun 2021 //
GLOBENEWSWIRE
Israel`s VBL Therapeutics hit with CMC delays in ovarian cancer study
15 Jun 2021 //
ENDPTS
VBL Announces Addition of Progression Free Survival as a Primary Endpoint
03 Jun 2021 //
GLOBENEWSWIRE
VBL to Provide an Update on the OVAL Ph3 Registration Enabling Study of VB-111
20 May 2021 //
GLOBENEWSWIRE
Update on the design of a Phase III Precision Medicine trial with the Diabetes
04 Mar 2021 //
PRNEWSWIRE
VBL Announces Data Safety Monitoring Committee Provides Green Light
22 Feb 2021 //
BIOSPACE
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
29 Dec 2020 //
GLOBENEWSWIRE
Mid-stage study underway on VBL`s VB-111 in colorectal cancer
09 Sep 2020 //
SEEKINGALPHA
Successful Completion Regarding Proposed Clinical Development of VB-601 of VBL
08 Sep 2020 //
GLOBENEWS WIRE
VBL’s ovarian cancer drug comes though interim phase 3 review
13 Aug 2020 //
FIERCE BIOTECH
VBL Announces Second Successful Pre-planned Interim Analysis a +VE Data Safety
12 Aug 2020 //
GLOBENEWSWIRE
VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Antibodies
04 Jun 2020 //
GLOBENEWSWIRE
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study
01 Jun 2020 //
GLOBENEWSWIRE
VBL First-in-class MOSPD2 Antibodies Show Potential for CNS Inflammation
04 May 2020 //
STREETINSIDER
